The U.S. Food and Drug Administration has approved PTC Therapeutics' oral drug to treat a rare inherited metabolic disorder ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the most profitable biotech stocks to invest in now. On July 23, analyst ...

The U.S. Food and Drug Administration (FDA) has approved PTC Therapeutics (NASDAQ:PTCT) oral drug Sephience to treat ...

The FDA approved PTC Therapeutics' new oral drug Sephience for treating phenylketonuria, a rare genetic disorder. It offers a new option as existing treatments face limitations and revenue declines.

Ascendis’ likely approval of TransCon CNP for achondroplasia poses a major threat to BioMarin’s best-selling drug. Read why I ...

Wolfe Research projects Palynziq sales of $648 million, compared to consensus estimates of $669 million, and maintains its bullish stance on BioMarin shares despite the potential for Sephience to ...

Phenylketonuria Treatment Market Share Market Segmentation Based on the Drugs to Witness Growth The market is segmented into Kuvan, CNSA-001, SYNB1618, Palynziq, and other drugs.